Literature DB >> 11467634

The decision-making value of magnetic resonance cholangiopancreatography in patients seen in a referral center for suspected biliary and pancreatic disease.

A V Sahai1, D Devonshire, K G Yeoh, C Kay, D Feldman, I Willner, J Farber, R Patel, P R Tamasky, J T Cunningham, T Trus, R H Hawes, P B Cotton.   

Abstract

OBJECTIVE: To assess the ability of MRCP to alter the differential diagnosis and to prevent diagnostic and/or therapeutic ERCP. The diagnostic accuracy of magnetic resonance cholangiopancreatography (MRCP) for biliary and pancreatic disease is well documented. Some believe MRCP may prevent diagnostic ERCP or add useful information, however there are no reports of its impact on clinical management.
METHODS: Consecutive patients referred for ERCP underwent clinic evaluation, then MRCP, and then ERCP. In Phase 1, the number of differential diagnoses and the perceived need for diagnostic ERCP were evaluated after each step by the endoscopist who performed the ERCP. In Phase 2, the process was repeated after presenting clinical information and MRCP results to different individual physicians: another endoscopist, a hepatologist, a radiologist, and a surgeon (all were blinded to ERCP results).
RESULTS: Forty patients were enrolled. Clinical contexts were jaundice (19.7%), abnormal liver enzymes (42.6%), abdominal pain (11.5%), recurrent acute pancreatitis (11.5%), and suspected complications of chronic pancreatitis (14.7%). In Phase 1, adding MRCP information to diagnostic ERCP information did not change the mean number of differential diagnoses significantly and prevented no therapeutic ERCP. In Phase 2, adding MRCP to clinical information only (without ERCP) reduced the differential diagnosis significantly for the radiologist and the surgeon only and would have prevented < or =3% of diagnostic and therapeutic ERCP for all physicians.
CONCLUSION: The value of MRCP information may be limited if patient selection is inappropriate and may differ in physicians depending on their speciality.

Entities:  

Mesh:

Year:  2001        PMID: 11467634     DOI: 10.1111/j.1572-0241.2001.03965.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

Review 1.  The role of magnetic resonance cholangiopancreatography in patients with suspected biliary obstruction.

Authors:  Mannudeep Kalra; Dushyant Sahani; Aamir Ahmad; Sanjay Saini
Journal:  Curr Gastroenterol Rep       Date:  2002-04

2.  Diagnostic role of secretin-enhanced MRCP in patients with unsuccessful ERCP.

Authors:  László Czakó; Tamás Takács; Zita Morvay; László Csernay; János Lonovics
Journal:  World J Gastroenterol       Date:  2004-10-15       Impact factor: 5.742

3.  Which imaging modalities should be used for biliary strictures of unknown aetiology?

Authors:  Dirk Domagk; Johannes Wessling; Beate Conrad; Roman Fischbach; Christina Schleicher; Werner Böcker; Norbert Senninger; Achim Heinecke; Walter Heindel; Wolfram Domschke; Torsten Kucharzik
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

4.  Impact of magnetic resonance cholangiography in managing liver-transplanted patients: preliminary results of a clinical decision-making study.

Authors:  L Cereser; R Girometti; G Como; C Molinari; P Toniutto; D Bitetto; C Zuiani; M Bazzocchi
Journal:  Radiol Med       Date:  2011-07-09       Impact factor: 3.469

5.  Preoperative MRCP to detect choledocholithiasis in acute calculous cholecystitis.

Authors:  Hon-Phin Wong; Yu-Lun Chiu; Bei-Hao Shiu; Lu-Chang Ho
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-07       Impact factor: 7.027

6.  Giant choledochal calculosis: surgical treatment.

Authors:  Hasan Bektas; Yigit Duzkoylu; Ekrem Cakar; Kenan Buyukasık; Sukru Colak
Journal:  N Am J Med Sci       Date:  2014-10

7.  Factors and Outcomes Associated with MRCP Use prior to ERCP in Patients at High Risk for Choledocholithiasis.

Authors:  Gobind Anand; Yuval A Patel; Hsin-Chieh Yeh; Mouen A Khashab; Anne Marie Lennon; Eun Ji Shin; Marcia I Canto; Patrick I Okolo; Anthony N Kalloo; Vikesh K Singh
Journal:  Can J Gastroenterol Hepatol       Date:  2016-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.